{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-103100","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2024-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.781139+00:00","generated_at":"2026-05-31T06:29:00.664333+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Invivyd doses first participants in Phase 1 trial of COVID-19 mAb candidate VYD2311","bullets":["Phase 1 trial (NCT06523153) of VYD2311 dosed first healthy volunteers; placebo-controlled, randomized.","Trial in Australia evaluating multiple dose levels, including intramuscular administration.","Preliminary data readouts expected Q4 2024; additional clinical readouts anticipated in 2025.","VYD2311 discovered via affinity maturation against recent SARS-CoV-2 variants; high in vitro potency.","Program builds on PEMGARDA (pemivibart), which received FDA EUA for COVID-19 PrEP in immunocompromised."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-103100","json":"https://secwatch.observer/filing/0000950170-24-103100.json","markdown":"https://secwatch.observer/filing/0000950170-24-103100.md","text":"https://secwatch.observer/filing/0000950170-24-103100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000095017024103100/0000950170-24-103100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000095017024103100/ivvd-20240904.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:29:00.664333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}